JERSEY CITY, N.J., May 21, 2024 /PRNewswire/ -- InsightAce Analytic
Pvt. Ltd. announces the release of a market assessment report on
the "Global Next Generation Drug Conjugates Market – By
Type (Peptide Receptor Radionuclide Therapy, Ligand mediated RNAi
Conjugate, Ligand Conjugated Anti Sense Medicine and Peptide Drug
Conjugate), By Type of Targeting Ligand (Amino Sugar, Peptide,
Lipid, Small Molecule and Virus-like Particles), By Type of Payload
(Peptide, Small Molecule, Oligonucleotide, Radionuclide), By Type
of Therapy (Monotherapy, Combination Therapy), By Route of
Administration, By Target Indications, By Region, Trends, Industry
Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the
Global Next Generation Drug Conjugates Market is valued at
US$ 2.61 Bn in 2023, and it is expected to reach
US$ 7.94 Bn by 2031, with a
CAGR of 15.1% during the forecast period of
2024-2031.
Request for Free Sample Pages:
https://www.insightaceanalytic.com/report/next-generation-drug-conjugates-market/2482
Next Generation Drug Conjugates Market Report Scope:
Report
Attribute
|
Specifications
|
Market Size Value In
2023
|
USD 2.61 Bn
|
Revenue Forecast In
2031
|
USD 7.94 Bn
|
Growth Rate
CAGR
|
CAGR of 15.1% from 2024
to 2031
|
Quantitative
Units
|
Representation of
revenue in US$ Mn and CAGR from 2024 to 2031
|
Historic
Year
|
2019 to 2023
|
Forecast
Year
|
2024-2031
|
Report
Coverage
|
The forecast of
revenue, the position of the company, the competitive market
structure, growth prospects, and trends
|
Segments
Covered
|
By Type, By Targeting
Ligand, By Payload, By Therapy, By Route of Administration, By
Indications and By Region
|
Regional
Scope
|
North America; Europe;
Asia Pacific; Latin America; Middle East & Africa
|
Country
Scope
|
U.S.; Canada; U.K.;
Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain;
South East Asia; South Korea
|
Growth of the next-generation drug conjugates market is driven by
several factors, such as the recent accelerated approvals of
various next-generation drug conjugates and the keen interest shown
by the big pharma players in forging strategic alliances with
the next-generation drug conjugate developers.
The ever-growing rise in medicare costs, along with the
increasing burden of rare disease indications, prompted the
stakeholders to look for alternatives to conventional therapies. As
a result, the next-generation conjugates combine cytotoxic drugs
with targeting agents, enhancing drug efficacy while reducing
systemic toxicity. Deeper cellular penetration and permeability
have emerged as viable targeted therapeutics for rare disease
indications, including cancers.
List of Prominent Players in the Next Generation Drug
Conjugates Market:
- Advanced Accelerator Applications
- Alnylam Pharmaceuticals
- Arrowhead Pharmaceuticals
- Dicerna Pharmaceuticals
- Geron Corporation
- Ionis Pharmaceuticals
- Dyne Therapeutics, Inc.
- Ambrx Biopharma, Inc. (Johnson & Johnson Services,
Inc.)
- Vincerx Pharma
- Tubulis Technologies
- Nurix Therapeutics, Inc.
- Other Prominent Players
Order 180 Pages Full Report
@ https://www.insightaceanalytic.com/buy-report/2482
Market Dynamics:
Drivers:
The growth of the next generation drug conjugates (NGDCs) market
is driven by several key factors. Technological advancements, such
as improved linker technologies and versatile applications, enhance
drug efficacy and safety.
The rising prevalence of chronic diseases, particularly cancer
and genetic disorders, fuels demand for targeted therapies.
Strategic industry collaborations and acquisitions, like Pfizer's
purchase of Seagen, accelerate innovation and market expansion.
Favorable regulatory environments support expedited review
processes and clear development guidelines. Additionally,
significant investment in research and development, supported by
funding and innovative platforms, drives the discovery and
optimization of new NGDCs. These combined factors contribute to the
rapid advancement and adoption of NGDCs in modern medicine.
Challenges:
The global next-generation drug conjugates market faces several
formidable challenges. One of the primary obstacles is the high
development cost associated with these therapies. The complex
manufacturing processes required for drug conjugates involve
sophisticated technology and stringent quality control measures,
making scalability difficult and expensive. Additionally, the
regulatory landscape presents significant hurdles; furthermore,
gaining permission from regulatory bodies like the FDA and EMA is a
time-consuming and expensive process that frequently necessitates
substantial clinical trials to prove safety and efficacy.
Another major challenge is ensuring the stability and efficacy
of drug conjugates. In order to be effective, these therapies must
both release the therapeutic agent at the target site in a
controlled manner and be stable under physiological conditions.
Balancing these requirements while minimizing toxicity is a complex
scientific and technical task. Patents and proprietary technology
can restrict the capacity of new companies to enter the market and
innovate, which further complicates intellectual property
issues.
Regional Trends:
The North American next generation drug conjugates market is
growing due to advanced healthcare infrastructure and significant
R&D investments. Key players in the region are driving
innovation in targeted cancer therapies, leveraging cutting-edge
technologies for drug conjugation. The increasing cases of cancer
and the rising demand for personalized medicine boost the market.
Favorable regulatory policies further stimulate market growth,
allowing swift approval and commercialization of novel drug
conjugates.
Moreover, strategic collaborations between pharmaceutical
companies and research institutions fuel the development of
next-generation therapies. With a robust pipeline and expanding
applications beyond oncology, the North American market for drug
conjugates is poised for sustained expansion.
Curious About This Latest Version of The Report? Enquiry
Before Buying:
https://www.insightaceanalytic.com/enquiry-before-buying/2482
Recent Developments:
- In April 2023, Novartis
entered into a licensing agreement with 3B Pharmaceuticals. 3B Pharmaceuticals is a German-based company
involved in the growth of peptide receptor radionuclide therapy
(PRRT) candidates targeting fibroblast activation protein (FAP)
receptors.
- In March 2023,
Japan-based PeptiDream signed
strategic partnership with US-based RayzeBio to develop a
peptide-radioisotope (RI) conjugate against Glypican-3 ("GPC3")
expressed in liver cancers.
- In March 2023, The USFDA
accepted Ionis Pharmaceutical's New Drug Application (NDA) for its
investigational antisense medication Eplontersen, which is intended
for patients with hereditary transthyretin-mediated amyloid
polyneuropathy (ATTRv-PN). After Amvuttra (vutrisiran) from
Alnylam, Eplontersen will be the second medication licensed for the
treatment of hereditary transthyretin-mediated amyloid
polyneuropathy (ATTRv-PN).
For More Customization @
https://www.insightaceanalytic.com/customisation/2482
Segmentation of Next Generation Drug Conjugates
Market-
Next Generation Drug Conjugates Market- By Type
- Peptide Receptor Radionuclide Therapy (Peptide Radionuclide
Conjugate)
- Ligand-mediated RNAi Conjugate
- Ligand Conjugated Antisense Medicine
- Peptide Drug Conjugate
Next Generation Drug Conjugates Market- By Targeting
Ligand
- Amino Sugar
- Lipid
- Peptide
- Small Molecule
- Virus-like Particles
Next Generation Drug Conjugates Market- By Payload
- Peptide
- Small Molecule
- Oligonucleotide
- Radionuclide
Next Generation Drug Conjugates Market- By Therapy
- Monotherapy
- Combination Therapy
Next Generation Drug Conjugates Market- By Route of
Administration
- Intravenous
- Subcutaneous
- Others
Next Generation Drug Conjugates Market- By
Indications
- Gastroenteropancreatic Neuroendocrine Tumors
- Prostate Cancer
- Leptomeningeal Carcinomatosis caused by Breast Cancer Brain
Metastases
- Hereditary Transthyretin Amyloidosis
- Atherosclerotic Cardiovascular Diseases
- Severe Hypertriglyceridemia
- Hereditary Angioedema
- Acute Hepatic Porphyria
- Primary Hyperoxaluria
- Heterozygous Familial Hypercholesterolemia
- Hemophilia
- Low-Risk Myelodysplastic Syndrome
- Myelofibrosis
- Familial Chylomicronemia Syndrome
- Alpha-1 Antitrypsin Deficiency Liver Disease
Next Generation Drug Conjugates Market- By Region
North America-
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and
Africa
Why should buy this report:
- To receive a comprehensive analysis of the prospects for global
next generation drug conjugates market
- To receive industry overview and future trends of global next
generation drug conjugates market
- To analyze the next generation drug conjugates market drivers
and challenges
- To get information on the next generation drug conjugates
market size value (US$ Mn) forecast till 2031
- Major Investments, Mergers & Acquisition in global next
generation drug conjugates market industry
Other Related Reports Published by InsightAce
Analytic:
Antibody Drug Conjugates (ADCs) – Linker and Conjugation
Technologies Market
Conjugation and Labeling Services Market
Peptide–Drug Conjugates (PDCs) Market
Antibody Discovery Market
About Us:
InsightAce Analytic is a market research and consulting firm
that enables clients to make strategic decisions. Our qualitative
and quantitative market intelligence solutions inform the need for
market and competitive intelligence to expand businesses. We help
clients gain competitive advantage by identifying untapped markets,
exploring new and competing technologies, segmenting potential
markets and repositioning products. Our expertise is in providing
syndicated and custom market intelligence reports with an in-depth
analysis with key market insights in a timely and cost-effective
manner.
Contact Us:
InsightAce Analytic PVT. LTD
Tel.: +1 551 226 6109
Email: info@insightaceanalytic.com
Follow us on LinkedIn:
https://www.linkedin.com/company/insightace-analytic-pvt-ltd/
Logo:
https://mma.prnewswire.com/media/1729637/InsightAce_Analytic_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/next-generation-drug-conjugates-market-worth-usd-7-94-billion-to-2031---exclusive-report-by-insightace-analytic-pvt-ltd-302151263.html